Business model

Future plans and intentions

Not only is the Cromo-T therapy predicted to have a higher success rate than existing methods, such improved efficacy will also be more cost effective.

The technology will be introduced to the market using two different strategies. One is to enable the pharmaceutical industry to utilize our technology via license. This strategy will initially be targeted to pharmaceutical companies working with CAR-T. The other strategy is to self-manage our distributions through licenses to GMP-certified labs worldwide. These labs will subsequently provide hospitals and cancer patients with Cromo-T.

We believe these two strategies align well with the vision of decentralizing the Cromo-T cell therapy and making the technology available worldwide.

Worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths  occurred in 2020.